Monte Rosa announced that its Investigational New Drug submission for MRT-6160 has been accepted by the U.S. Food and Drug Administration. Initiation of a Phase 1 single ascending dose/multiple ascending dose study is expected this summer and initial clinical results are anticipated in Q1 2025
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
- These 2 ‘Strong Buy’ Penny Stocks Could Jump at Least 300%, Says Piper Sandler
- Monte Rosa Therapeutics Reports Progress on Drug Development
- Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Questions or Comments about the article? Write to editor@tipranks.com